

Express Mail Label No.: EJ770260474US
Date of Deposit: September 5, 2000



Attorney Docket No. 00960-514 (CBM-14)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
SEP 12 2000
OFFICE OF PETITIONS
APPLICANT(S) CANCELLED 09
PATENT & TRADEMARK OFFICE
ASSIGNEE: Sampath et al.
SERIAL NO.: 09/445,328 EXAMINER: Not Yet Assigned
FILING DATE: December 7, 1999 ART UNIT: 1646
FOR: THERAPIES FOR ACUTE RENAL FAILURE

[Signature]

September 5, 2000
Boston, Massachusetts

Assistant Commissioner for Patents
Washington, D.C. 20231

PETITION TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.48

The present Petition is filed under 37 C.F.R. §1.48(a) to correct the inventive entity set forth in error in the executed Declaration previously filed in the above-identified application. Applicants hereby petition for Slobodon Vukicevic to be added as an inventor of the above-identified application. As required under 37 C.F.R. §1.48(a), Applicants submit herewith:

- Statement to Correct Inventorship. 37 C.F.R. §1.48(a)(1);
- Executed Combined Declaration and Power of Attorney by Actual Inventors. 37 C.F.R. §1.48 (a)(2);
- Petition Fee set forth in 37 C.F.R. §1.17(i) (\$130.00). 37 C.F.R. §1.48(a)(3); and
- Written Consent of the Assignee. 37 C.F.R. §1.48(a)(4).

Applicants believe that the appropriate fees due in connection with this submission are provided herewith. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, (Reference No. 00960-514, CBM-14).

Respectfully submitted,

Shelby J. Walker

Ivor R. Elrify, Reg. No. 39,529
Michel Morency, Limited Recognition
Shelby J. Walker, Reg. No. 45,192
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

09/11/2000 CNGUYEN 00000068 08445328

01 FC:122

130.00 OP

Express Mail Label No.: EJ770260474US
Date of Deposit: September 5, 2000



Attorney Docket No.: 00960-514 (CBM-14)

RECEIVED

SEP 18 2000

PC 2700 MAIL ROOM

RECEIVED

SEP 12 2000

OFFICE OF PETITIONS

APPLICANT(S) Sampath & Cohen
ASSIGNEE: CREATIVE BIOMOLECULES, INC.
SERIAL NO.: 08/445,328 EXAMINER: Not Yet Assigned
FILING DATE: December 7, 1999 ART UNIT: 1646
FOR: THERAPIES FOR ACUTE RENAL FAILURE

Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT OF ADDED INVENTOR, SLOBODON VUKICEVIC

This is a statement under 37 C.F.R. § 1.48(a) from the undersigned, Slobodon Vukicevic, who is to be added as an inventor to the above-identified patent application. The error of failing to include me, Slobodon Vukicevic, as an inventor occurred without any deceptive intention on my part.

Respectfully submitted,

Slobodon Vukicevic

Date: 7/24/00



Express Mail Label No.: EJ770260474US
Date of Deposit: September 5, 2000



Attorney Docket No.: 00960-514 (CBM-14)

RECEIVED
SEP 18 2000
PCT 2700 MAIL ROOM

RECEIVED

SEP 12 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

OFFICE OF PETITIONS

CONSENT OF ASSIGNEE TO CHANGE OF INVENTORSHIP

CREATIVE BIOMOLECULES, INC., a corporation and owner of the above-identified patent application, PCT/US98/03197 filed 5 May 1998, assignment recorded on December 12, 1999, at Reel/Frame 010530/0388, hereby consents to the addition of Slobodon Vukicevic as an inventor of the above-identified application. 37 C.F.R. §1.48(a)(4).

CREATIVE BIOMOLECULES, INC. certifies under 37 C.F.R. § 3.73(b) that it is the Assignee of the entire right, title and interest in the patent application identified above by virtue of assignment of the patent application identified above.

I, the undersigned, am empowered to act on behalf of the Assignee. Acting on behalf of the Assignee, I have reviewed all the documents in the chain of title of the patent application identified above and, to the best of my knowledge and belief, title is in the Assignee identified above.

I, the undersigned, hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Respectfully submitted,

Cheryl Lawton
Vice President, General Counsel
CREATIVE BIOMOLECULES, INC.

Date: 7-24-00